Dinca Ana, Chien Wei-Ming, Chin Michael T
Department of Pathology, University of Washington, Seattle, WA 98109, USA.
Department of Medicine, Division of Cardiology, University of Washington, Seattle, WA 98109, USA.
Int J Mol Sci. 2016 Feb 22;17(2):263. doi: 10.3390/ijms17020263.
Protein therapy exhibits several advantages over small molecule drugs and is increasingly being developed for the treatment of disorders ranging from single enzyme deficiencies to cancer. Cell-penetrating peptides (CPPs), a group of small peptides capable of promoting transport of molecular cargo across the plasma membrane, have become important tools in promoting the cellular uptake of exogenously delivered proteins. Although the molecular mechanisms of uptake are not firmly established, CPPs have been empirically shown to promote uptake of various molecules, including large proteins over 100 kiloDaltons (kDa). Recombinant proteins that include a CPP tag to promote intracellular delivery show promise as therapeutic agents with encouraging success rates in both animal and human trials. This review highlights recent advances in protein-CPP therapy and discusses optimization strategies and potential detrimental effects.
与小分子药物相比,蛋白质疗法具有多种优势,并且越来越多地被开发用于治疗从单酶缺乏症到癌症等各种疾病。细胞穿透肽(CPPs)是一类能够促进分子货物跨质膜运输的小肽,已成为促进外源性递送蛋白质细胞摄取的重要工具。尽管摄取的分子机制尚未完全明确,但经验表明,CPPs能够促进包括分子量超过100千道尔顿(kDa)的大蛋白在内的各种分子的摄取。包含CPP标签以促进细胞内递送的重组蛋白作为治疗剂显示出前景,在动物和人体试验中均取得了令人鼓舞的成功率。本综述重点介绍了蛋白质-CPP疗法的最新进展,并讨论了优化策略和潜在的有害影响。